相关实验视频
Updated: Aug 18, 2026

14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
在喘患者中,每天两次服用沙美特醇后对沙布他醇的支气管扩展剂过敏
1Department of Clinical Pharmacology, Ninewells Hospital, University of Dundee, UK.
Lancet (London, England)
|July 22, 1995
概括
持续使用沙米特醇可能会使喘患者对沙布他的支气管扩展剂反应减弱. 这项研究发现,尽管维持了疾病控制,但salmeterol的反应和β-2 adrenoceptor密度降低了.
科学领域:
- 药理学 药理学 是一个学科.
- 呼吸系统医学 呼吸系统医学
- 临床试验 临床试验
背景情况:
- 关于在喘管理中定期使用β-2激动剂存在担忧.
- 越来越多地使用长效β-2激动剂 (LABAs),如沙米特醇.
- 持续暴露于LABA对急性支气管扩展剂反应的影响需要评估.
研究的目的:
- 为了评估连续每天两次服用沙米特醇是否会使急性支气管扩展剂对沙布塔摩尔的反应变得模糊.
- 为了研究贝塔-2上腺素受体密度的变化与沙米特醇治疗.
- 为了评估沙米特醇在治疗期间控制喘的有效性.
主要方法:
- 在17名喘患者中进行双盲,安慰剂控制,交叉研究.
- 患者在4周内每天两次接受salmeterol 50mcg或安慰剂.
- 测量了组胺挑战和沙布塔摩尔剂量反应曲线 (FEV1,PEFR).
主要成果:
- 与安慰剂相比,salmeterol治疗显著降低了对萨尔布塔摩尔的支气管扩展剂反应.
- 为了获得FEV1和PEFR的改善,需要高出salbutamol剂量的2.5倍和4倍.
- 淋巴细胞β-2 adrenoceptor密度显著下降后salmeterol.
结论:
- 持续使用沙米特醇可能会减弱沙布他的急性支气管扩展作用.
- 降低β-2上腺素受体密度可能是这种模糊反应的基础.
- 沙米特醇保持了喘控制,早晨PEFR的改善证明了这一点.
相关概念视频
Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

